Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596024 · ClinicalTrials.gov registry record · Phase 2
Lutein and Alzheimer's Disease Study
A Phase 2 study, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT00596024 is a Phase 2 study that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 3 participants.
The verdict
NCT00596024, a Phase 2 study, was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxidants that have important functions for human health. Carotenoids are known to reduce oxidative damage, but their effects have not been studied in AD patients. The objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in AD patients.
Interventions
- DIETARY_SUPPLEMENT placebo
- DIETARY_SUPPLEMENT lutein/zeaxanthin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00596024
The ClinicalTrials.gov registry entry for NCT00596024 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00596024 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00596024 about?
NCT00596024 is a clinical study titled "Lutein and Alzheimer's Disease Study". Oxidative damage by free radicals may be involved in causing Alzheimer's disease (AD). Free radicals may lead to death of nerve cells and decline in brain function. Certain antioxidants may suppress this free radical damage associated with AD. Carotenoids are a family of naturally occurring antioxid...
What is the current status of trial NCT00596024?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2007-12. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00596024?
The interventions under investigation include: placebo (DIETARY_SUPPLEMENT), lutein/zeaxanthin (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00596024?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.